Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 8:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: imiquimod Clear all
Completed Phase 3 Interventional Results available

Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)

NCT00603798
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Imiquimod cream, Placebo cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
26
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Encino, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2010 · Synced Sep 24, 2026, 8:59 AM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts

NCT00674739
View directory record Official record
Conditions
Genital Warts
Interventions
Imiquimod, 3.75% imiquimod cream, placebo cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
30
States / cities
Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated May 23, 2011 · Synced Sep 24, 2026, 8:59 AM EDT
Completed Phase 3 Interventional Results available

Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions

NCT02135419
View directory record Official record
Conditions
Anal Cancer, High-grade Squamous Intraepithelial Lesion, HIV Infection, Human Papilloma Virus Infection
Interventions
imiquimod, fluorouracil, infrared photocoagulation therapy, thermal ablation therapy, laser therapy, clinical observation, laboratory biomarker analysis
Drug · Device · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
35 Years and older
Enrollment
4,446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
24
States / cities
Los Angeles, California • Palm Springs, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Sep 24, 2026, 8:59 AM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

Basal Cell Carcinoma Chemoprevention Trial

NCT05212246
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
5% Imiquimod cream, Placebo Vehicle Control Cream
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
1,630 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 24, 2026, 8:59 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

NCT03180684
View directory record Official record
Conditions
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar Dysplasia, Vulvar Intraepithelial Neoplasia (VIN), VIN2, VIN3, Pre-cancerous Lesions of the Vulva, Human Papillomavirus (HPV)
Interventions
VGX-3100, Imiquimod 5% Cream, CELLECTRA™ 2000
Biological · Drug · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
15
States / cities
Newark, Delaware • Augusta, Georgia • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Sep 24, 2026, 8:59 AM EDT
Terminated Phase 2 Interventional Results available

Imiquimod for Preventing Keloid Recurrence

NCT03760250
View directory record Official record
Conditions
Keloid
Interventions
Imiquimod 5% cream
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Sep 24, 2026, 8:59 AM EDT
Terminated Phase 2 Interventional Results available

The Effects of Aldara as an Adjunct to Laser Treatment

NCT00979550
View directory record Official record
Conditions
Port Wine Stains
Interventions
Imiquimod, non-medicated petroleum cream
Drug
Lead sponsor
Henry Vasconez
Other
Eligibility
2 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Sep 24, 2026, 8:59 AM EDT
Completed Phase 1 Interventional

Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer

NCT00079300
View directory record Official record
Conditions
Non-melanomatous Skin Cancer
Interventions
imiquimod, conventional surgery
Drug · Procedure
Lead sponsor
National Naval Medical Center
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2013 · Synced Sep 24, 2026, 8:59 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence

NCT00129519
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
Imiquimod 5% cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
3
States / cities
Grass Valley, California • Loma Linda, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2010 · Synced Sep 24, 2026, 8:59 AM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL

NCT02689726
View directory record Official record
Conditions
HPV 16- and/or HPV 18-Infected Women With Normal Cytology, ASCUS, or LSIL
Interventions
GTL001+, Aldara
Drug
Lead sponsor
Genticel
Industry
Eligibility
25 Years to 65 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Louisville, Kentucky • Raleigh, North Carolina • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Sep 24, 2026, 8:59 AM EDT
Completed Phase 4 Interventional

Investigating the Effect of Topical Imiquimod on Sebaceous Hyperplasia

NCT06840470
View directory record Official record
Conditions
Sebaceous Hyperplasia
Interventions
Imiquimod 5% Topical Cream
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 24, 2026, 8:59 AM EDT
Terminated Phase 1 Interventional

Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer

NCT03982004
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Epicutaneous cryoimmunotherapy, Topical imiquimod, Pembrolizumab, Dermatologic Quality of Life Index, Functional Assessment of Cancer Therapy, Intra-lesional GM-CSF, Cry-AC, Cutaneous tumor biopsy, Peripheral blood draw for research
Device · Drug · Other + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 20, 2021 · Synced Sep 24, 2026, 8:59 AM EDT
Completed Not applicable Interventional

Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT00801320
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Tumor collection
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Sep 24, 2026, 8:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Immunologic Profile of Chronically Photodamaged Skin

NCT02889159
View directory record Official record
Conditions
Photoaged Skin, Normal Skin
Interventions
Candida albicans antigen, histamine phosphate, imiquimod 5% cream, Tape Stripping
Biological · Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 24, 2026, 8:59 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

NCT03872947
View directory record Official record
Conditions
Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
TRK-950, Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD
Biological · Drug
Lead sponsor
Toray Industries, Inc
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
13
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 24, 2026, 8:59 AM EDT
Completed Phase 2 Interventional

Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream

NCT00335179
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Aldara (imiquimod 5% cream), Vehicle cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2010 · Synced Sep 24, 2026, 8:59 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses

NCT02120898
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Imiquimod, Zyclara®, Vehicle Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
27
States / cities
Birmingham, Alabama • Fremont, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Sep 24, 2026, 8:59 AM EDT
Completed Phase 4 Interventional Results available

Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis

NCT00116649
View directory record Official record
Conditions
Keratosis
Interventions
imiquimod cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
32
States / cities
Phoenix, Arizona • Encino, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2010 · Synced Sep 24, 2026, 8:59 AM EDT
Completed Not applicable Interventional Results available

Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna

NCT00707174
View directory record Official record
Conditions
Cancer, Lentigo Maligna
Interventions
Imiquimod Cream, Tazarotene Cream 0.1%
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Sep 24, 2026, 8:59 AM EDT
Recruiting Phase 1Phase 2 Interventional

Topical Imiquimod Treatment of Oral Dysplasia

NCT07210775
View directory record Official record
Conditions
Oral Dysplasia, Leukoplakia Oral, Leukoplakia
Interventions
Imiquimod (topical use)
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 24, 2026, 8:59 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia

NCT00788164
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition, HPV Disease, Human Papilomavirus
Interventions
TA-HPV, pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine, imiquimod
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Sep 24, 2026, 8:59 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies

NCT02224599
View directory record Official record
Conditions
Progressive Solid Malignancies, Refractory Solid Malignancies, Cancer
Interventions
TAPA-pulsed DC vaccine, Cyclophosphamide Pill, Imiquimod Topical Cream
Biological · Drug
Lead sponsor
Kiromic BioPharma Inc.
Industry
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 24, 2026, 8:59 AM EDT
Completed Not applicable Interventional Results available

Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks

NCT00585247
View directory record Official record
Conditions
Port Wine Stain
Interventions
Imiquimod, Placebo
Drug · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
Not listed
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Sep 24, 2026, 8:59 AM EDT
Completed Phase 2 Interventional Results available

Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)

NCT02864147
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia, Cervical Dysplasia
Interventions
9-valent HPV vaccine, Imiquimod
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Sep 24, 2026, 8:59 AM EDT